Plain-English translation of NCT05357651 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial—the earliest stage of human testing—for a new medication called that is designed to help your immune system fight cancer. The medication works by targeting two specific pathways that cancer cells use to hide from your body's natural defenses. Researchers will give this treatment to about 100 patients with advanced solid tumors or lymphoma to see if it is safe and how well it works.
Many patients with advanced cancers do not respond well to current immune-based treatments, or their cancers stop responding over time. This medication targets two different immune checkpoints instead of just one, which doctors hope may help overcome cancer's ability to escape the immune system.
You likely qualify if…
You likely don't qualify if…
You will receive the medication by intravenous infusion (through an IV in your arm) at a hospital or clinic. The trial has two main parts: first, researchers will test different dose levels to find the safest and most effective dose, then they will enroll more patients at the best dose found. You will have regular clinic visits, blood tests, and imaging scans to monitor how your body responds to the treatment and whether your cancer is responding.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
L & L Bio Co., Ltd., Ningbo, China
Enrollment target
~100 participants
Started
August 2022
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yan Luan
Shanghai Pulmonary Hospital, Shanghai, China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.